Coagulation factor IX compositions and methods of making and using same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/36
C07K-014/745
C12N-009/64
A61K-038/00
출원번호
US-0710077
(2015-05-12)
등록번호
US-9376672
(2016-06-28)
발명자
/ 주소
Schellenberger, Volker
Stemmer, Willem P.
Geething, Nathan C.
To, Wayne
Silverman, Joshua
Wang, Chia-wei
Spink, Benjamin
출원인 / 주소
Amunix Operating Inc.
대리인 / 주소
Sterne, Kessler, Goldstein & Fox P.L.L.C.
인용정보
피인용 횟수 :
2인용 특허 :
203
초록▼
The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of
The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
대표청구항▼
1. A factor IX fusion protein comprising a factor IX polypeptide and an extended recombinant polypeptide (XTEN), said XTEN comprising an amino acid sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 35, 36, 37, 38, 43, 44, 45, and 46, wherein the XTEN is character
1. A factor IX fusion protein comprising a factor IX polypeptide and an extended recombinant polypeptide (XTEN), said XTEN comprising an amino acid sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 35, 36, 37, 38, 43, 44, 45, and 46, wherein the XTEN is characterized in that: (a) the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than 80% of the total amino acid residues of the XTEN: and(b) the XTEN is non-repetitive such that (i) the XTEN contains no three contiguous amino acids that are identical unless the amino acids are serine, or (ii) at least 80% of the XTEN comprises non-overlapping sequence motifs, each of the sequence motifs comprising about 9 to about 14 amino acid residues, wherein any two contiguous amino acid residues do not occur more than twice in each of the sequence motifs. 2. The factor IX fusion protein of claim 1, wherein the XTEN comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO 36. 3. The factor IX fusion protein of claim 1, wherein said XTEN comprises the amino acid sequence set forth in SEQ ID NO: 36. 4. The factor IX fusion protein of claim 1, wherein the XTEN comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 37. 5. The factor IX fusion protein of claim 1, wherein said XTEN comprises the amino acid sequence set forth in SEQ ID NO: 37. 6. The factor IX fusion protein of claim 1, wherein said factor IX polypeptide is linked at its C-terminus to the XTEN. 7. The factor IX fusion protein of claim 1 that is configured according to formula VII: (Gla)-(XTEN)u-(EGF1)-(XTEN)v-(EGF2)-(AP1)-(XTEN)w-(AP2)-(XTEN)x-(Pro)-(s)y-(XTEN)z VIIwherein independently for each occurrence,(a) Gla is a Gla domain of the factor IX polypeptide;(b) EGF1 is an EGF1 domain of the factor IX polypeptide;(c) EGF2 is an EFG2 domain of the factor IX polypeptide;(d) AP1 is a portion of an activator peptide domain of the factor IX polypeptide;(e) AP2 is a portion of an activator peptide domain of the factor IX polypeptide that includes at least a first cleavage sequence;(f) PRO is a protease domain of the factor IX polypeptide;(g) S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence;(h) XTEN is the extended recombinant polypeptide;(i) u is either 0 or 1;(j) v is either 0 or 1;(k) x is either 0 or 1;(1) y is either 0 or 1; and(m) z is either 0 or 1, with the proviso that u+v+x+y+z≧1. 8. The factor IX fusion protein of claim 1, which comprises more than one XTEN. 9. The factor IX fusion protein of claim 1, wherein said XTEN is incorporated between any two adjacent domains contained in said factor IX, wherein said two adjacent domains are selected from the group consisting of Gla, EGF1, EGF2, AP, and peptidase S1 (Pro). 10. The factor IX fusion protein of claim 1, wherein the XTEN comprises an amino acid sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 341, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, and 489. 11. The factor IX fusion protein of claim 10, wherein the XTEN comprises an amino acid sequence having at least 95% sequence identity to a sequence selected from SEQ ID NOs: 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 341, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, and 489. 12. The factor IX fusion protein of claim 11, wherein the XTEN comprises an amino acid sequence selected from SEQ ID NOs: 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 341, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, and 489. 13. The factor IX fusion protein of claim 12, wherein the XTEN comprises an amino acid sequence selected from SEQ ID NOs: 225, 229, 231, 239, 243, 249, 255, 257, 265, and 283. 14. The factor IX fusion protein of claim 13, wherein the fusion protein comprises SEQ ID NO: 229. 15. The factor IX fusion protein of claim 1, wherein the XTEN comprises an amino acid sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 61, 62, 63, 65, 66, 69, 71, 73, 74, 75, 76, 77, 78, 79, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, and 556. 16. The factor IX fusion protein of claim 15, wherein the XTEN comprises an amino acid sequence having at least 95% sequence identity to a sequence selected from SEQ ID NOs: 61, 62, 63, 65, 66, 69, 71, 73, 74, 75, 76, 77, 78, 79, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, and 556. 17. The factor IX fusion protein of claim 16, wherein the XTEN comprises an amino acid sequence selected from SEQ ID NOs: 61, 62, 63, 65, 66, 69, 71, 73, 74, 75, 76, 77, 78, 79, 492, 494, 496, 498, 500, 502, 504, 506 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, and 556. 18. The factor IX fusion protein of claim 17, wherein the XTEN comprises SEQ ID NO: 63 or 65. 19. The factor IX fusion protein of claim 1, wherein the fusion protein comprises an amino acid sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 602, 604, 606, 608, 612, 614, 616, and 618. 20. The factor IX fusion protein of claim 19, wherein the fusion protein comprises an amino acid sequence having at least 95% sequence identity to a sequence selected from SEQ ID NOs: 602, 604, 606, 608, 612, 614, 616, and 618. 21. The factor IX fusion protein of claim 20, wherein the fusion protein comprises an amino acid sequence selected from SEQ ID NOs: 602, 604, 606, 608, 612, 614, 616, and 618. 22. A polynucleotide encoding the factor IX fusion protein of claim 1. 23. A vector comprising the polynucleotide of claim 22. 24. A host cell comprising the polynucleotide of claim 22. 25. A method of producing a FIX fusion protein comprising culturing the host cell of claim 24 under suitable condition, wherein the FIX fusion protein is expressed. 26. A pharmaceutical composition comprising the factor IX fusion protein of claim 1. 27. A pharmaceutical composition comprising the polynucleotide of claim 22.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (203)
Curtis Joseph E. (Glendora CA) Helgerson Sam L. (Pasadena CA) Lundblad Roger L. (Chapel Hill NC) Liu Shu-Len (Cerritos CA), Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency.
Lillicrap David,CAX ; Cameron Cherie,CAX ; Notley Colleen,CAX ; Hoyle Horrocks L. Suzanne,CAX ; Hough Christine,CAX, Canine factor VIII gene, protein and methods of use.
Schellenberger, Volker; Silverman, Joshua; Stemmer, Willem; Wang, Chia-wei; Spink, Benjamin; Geething, Nathan; To, Wayne, Coagulation factor VII compositions and methods of making and using same.
Osterberg Thomas,SEX ; Fatouros Angelica,SEX, Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabi.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Composition for delivering bioactive agents for immune response and its preparation.
Qiu, Yihong; Bollinger, J. Daniel; Cheskin, Howard S.; Dutta, Sandeep; Engh, Kevin R.; Poska, Richard P., Controlled release formulation of divalproex sodium.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Davie Earl W. (9010 N.E. 22nd Pl. Bellevue WA 98004) Kurachi Kotoku (4022 N.E. 104 Ave. Seattle WA 98125), DNA preparation of Christmas factor and use of DNA sequences.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Hagen Frederick S. (Seattle WA) Murray Mark J. (Seattle WA) Busby Sharon J. (Seattle WA) Berkner Kathleen L. (Seattle WA) Insley Margaret Y. (Woodinville WA) Woodbury Richard G. (Seattle WA) Gray Cha, Expression of factor VII activity in mammalian cells.
Lenting, Petrus Johannes; Van Mourik, Jan Aart; Mertens, Koenraad; Pannekoek, Hans; Turecek, Peter; Schwarz, Hans-Peter; Scheiflinger, Friedrich, Factor VII polypeptide having factor VII:C activity.
Meulien Pierre (Strasbourg FRX) Pavirani Andrea (Strasbourg FRX), Factor VIII analog, preparation process, and pharmaceutical composition containing it.
Weimer, Thomas; Schulte, Stefan; Metzner, Hubert; Kronthaler, Ulrich; Lind, Holger; Lang, Wiegand, Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life.
Schellenberger, Volker; Silverman, Joshua; Stemmer, Willem P.; Wang, Chia-wei; Geething, Nathan; Cleland, Jeffrey L.; Spink, Benjamin, Growth hormone polypeptides and methods of making and using same.
Schellenberger, Volker; Silverman, Joshua; Wang, Chia-wei; Stemmer, Willem P.; Geething, Nathan; Cleland, Jeffrey L., Growth hormone polypeptides and methods of making and using same.
Schellenberger, Volker; Silverman, Joshua; Stemmer, Willem P.; Wang, Chia-Wei; Geething, Nathan; Cleland, Jeffrey L., Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same.
Cunningham Brian C. (Piedmont CA) Lowman Henry (Hercules CA) Wells James A. (Burlingame CA), Human growth hormone variants having greater affinity for human growth hormone receptor at site 1.
Tice, Thomas R.; Lewis, Danny H.; Cowsar, Donald R.; Beck, Lee R., Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Turner Terry L. (Charlottesville VA) Howards Stuart S. (Charlottesville VA), Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Kuo George (San Francisco CA) Masiarz Frank (San Francisco CA) Truett Martha (Oakland CA) Valenzuela Pablo (San Francisco CA), Method and composition for preparation of factor VIIIC.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
D\Arrigo Joseph S. (Farmington CT), Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and the.
Spira Jack,SEX ; Widlund Lars,SEX ; Osterberg Thomas,SEX, Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives.
Jolly, Douglas J.; Chang, Stephen; Respess, James G.; DePolo, Nicholas J.; Hsu, David Chi-Tang; Ibanez, Carlos E.; Greengard, Judith; Will, Lee, Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders.
Idusogie Esohe Ekinaduese ; Mulkerrin Michael George ; Presta Leonard G. ; Shields Robert Laird, Methods for determining binding of an analyte to a receptor.
Schellenberger, Volker; Stemmer, Willem P.; Wang, Chia-wei; Scholle, Michael D.; Popkov, Mikhail; Gordon, Nathaniel C.; Crameri, Andreas, Methods for production of unstructured recombinant polymers and uses thereof.
Andrew S. Janoff ; Thomas D. Madden CA; Pieter R. Cullis CA; John J. Kearns ; Anthony G. Durning, Methods of preparing low-toxicity drug-lipid complexes.
Tice, Thomas R.; Dillon, Deborah L.; Mason, David W.; McRae-McFarlane, Amanda; Dahlstrom, Annica B., Microcapsules for administration of neuroactive agents.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Harrison Juan M. E. (Mountain View CA) Barclay Brian L. (Sunnyvale CA) Childers Jerry D. (Menlo Park CA) Wright Jeri D. (Dublin CA) Place Virgil A. (Kawaihae HI) Wong Patrick S. (Palo Alto CA), Oral osmotic device with hydrogel driving member.
Popescu Mircea C. ; Weiner Alan L. ; Recine Marie S. ; Janoff Andrew S. ; Estis Leonard ; Keyes Lynn D. ; Alving Carl R., Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use.
Capon Daniel J. (San Mateo CA) Lawn Richard M. (San Francisco CA) Levinson Arthur D. (Hillsborough CA) Vehar Gordon A. (San Carlos CA) Wood William I. (San Mateo CA), Preparation of functional human factor VIII in mammalian cells using methotrexate based selection.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Gelfand David H. (Oakland CA) Horn Glenn (Emeryville CA) Saiki Randall K. (Richmond CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Chapman Barbara ; Burke Rae Lyn ; Rasmussen Mirella Ezban,DKX ; Mikkelson Jan Moller,DKX, Protein complexes having Factor VIII:C activity and production thereof.
Chapman Barbara ; Burke Rae Lyn ; Rasmussen Mirella Ezban,DKX ; Mikkelson Jan Moller,DKX, Protein complexes having factor VIII:C activity and production thereof.
Chapman Barbara ; Burke Rae Lyn ; Rasmussen Mirella Ezban,DKX ; Mikkelson Jan Moller,DKX, Protein complexes having factor VIII:C activity and production thereof.
Van Ooyen Albert Johannes Joseph,NLX ; Pannekoek Hans,NLX ; Verbeet Martinus Philippus,NLX ; Van Leen Robert Willem,NLX, Proteins with Factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them.
van Ooyen Albert J. J. (Voorburg NLX) Pannekoek Hans (Aalsmeer NLX) Verbeet Martinus P. (Amsterdam NLX) van Leen Robert W. (Nijmegen NLX), Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical.
Albert Johannes Joseph Van Ooyen NL; Hans Pannekoek NL; Martinus Philippus Verbeet NL; Robert Willem Van Leen NL, Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them.
Edward M. Rudnic ; Beth A. Burnside ; Henry H. Flanner ; Sandra E. Wassink ; Richard A. Couch ; Jill E. Pinkett, Soluble form osmotic dose delivery system.
Rudnic Edward M. ; Burnside Beth A. ; Flanner Henry H. ; Wassink Sandra E. ; Couch Richard A. ; Pinkett Jill E., Soluble form osmotic dose delivery system.
Rudnic, Edward M.; Burnside, Beth A.; Flanner, Henry H.; Wassink, Sandra E.; Couch, Richard A.; Pinkett, Jill E., Soluble form osmotic dose delivery system.
D\Arrigo Joseph S. (23A Brickyard Rd. Farmington CT 06032), Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures.
Wheatley Margaret A. (Norristown PA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for controlled release of biologically active compounds.
Kenten John Henry,GBX ; Boss Michael Alan,GBX, Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing s.
Adler-Moore Jill ; Gamble Ronald C. ; Proffitt Richard T., Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics.
Schellenberger, Volker; Stemmer, Willem P.; Geething, Nathan C.; To, Wayne; Silverman, Joshua; Wang, Chia-wei; Spink, Benjamin, Coagulation factor IX compositions and methods of making and using same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.